scholarly journals B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

2010 ◽  
Vol 34 (3) ◽  
pp. 327-340 ◽  
Author(s):  
Matija Snuderl ◽  
Olga K. Kolman ◽  
Yi-Bin Chen ◽  
Jessie J. Hsu ◽  
Adam M. Ackerman ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
B Cell Lymphomas ◽  
Large B Cell Lymphoma ◽  
Pathologic Features ◽  
Large B Cell

scholarly journals BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines

2020 ◽  
Vol 4 (2) ◽  
pp. 356-366 ◽  
Author(s):  
Sarah T. Diepstraten ◽  
Catherine Chang ◽  
Lin Tai ◽  
Jia-nan Gong ◽  
Ping Lan ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lines ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
B Cell Lymphomas ◽  
Sustained Growth ◽  
Large B Cell Lymphoma ◽  
Bh3 Mimetic ◽  
Large B Cell

Abstract Dysregulated expression of BCL-2 family proteins allows cancer cells to escape apoptosis. To counter this, BH3-mimetic drugs that target and inhibit select BCL-2 prosurvival proteins to induce apoptosis have been developed for cancer therapy. Venetoclax, which targets BCL-2, has been effective as therapy for patients with chronic lymphocytic leukemia, and MCL-1–targeting BH3-mimetic drugs have been extensively evaluated in preclinical studies for a range of blood cancers. Recently, BCL-W, a relatively understudied prosurvival member of the BCL-2 protein family, has been reported to be abnormally upregulated in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and Hodgkin lymphoma patient samples. Therefore, to determine if BCL-W would be a promising therapeutic target for B-cell lymphomas, we have examined the role of BCL-W in the sustained growth of human BL- and DLBCL-derived cell lines. We found that CRISPR/CAS9-mediated loss or short hairpin RNA-mediated knockdown of BCL-W expression in selected BL and DLBCL cell lines did not lead to spontaneous apoptosis and had no effect on their sensitivity to a range of BH3-mimetic drugs targeting other BCL-2 prosurvival proteins. Our results suggest that BCL-W is not universally required for the sustained growth and survival of human BL and DLBCL cell lines. Thus, targeting BCL-W in this subset of B-cell lymphomas may not be of broad therapeutic benefit.

scholarly journals Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 90-99 ◽  
Author(s):  
Steven H. Swerdlow
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
Clinical Importance ◽  
B Cell Lymphoma ◽  
B Cell Lymphomas ◽  
Not Otherwise Specified ◽  
Large B Cell Lymphoma ◽  
Double Hit ◽  
Large B Cell

Abstract Identification of large B-cell lymphomas that are “extra-aggressive” and may require therapy other than that used for diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is of great interest. Large B-cell lymphomas with MYC plus BCL2 and/or BCL6 rearrangements, so-called ‘double hit’ (DHL) or ‘triple hit’ (THL) lymphomas, are one such group of cases often recognized using cytogenetic FISH studies. Whether features such as morphologic classification, BCL2 expression, or type of MYC translocation partner may mitigate the very adverse prognosis of DHL/THL is controversial. Classification of the DHL/THL is also controversial, with most either dividing them up between the DLBCL, NOS and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (BCLU) categories or classifying at least the majority as BCLU. The BCLU category itself has many features that overlap those of DHL/THL. Currently, there is growing interest in the use of MYC and other immunohistochemistry either to help screen for DHL/THL or to identify “double-expressor” (DE) large B-cell lymphomas, defined in most studies as having ≥40% MYC+ and ≥50%-70% BCL2+ cells. DE large B-cell lymphomas are generally aggressive, although not as aggressive as DHL/THL, are more common than DHL/THL, and are more likely to have a nongerminal center phenotype. Whether single MYC rearrangements or MYC expression alone is of clinical importance is controversial. The field of the DHL/THL and DE large B-cell lymphomas is becoming more complex, with many issues left to resolve; however, great interest remains in identifying these cases while more is learned about them.

Should Adolescents with NHL Be Treated as Old Children or Young Adults?

Hematology ◽  
2007 ◽  
Vol 2007 (1) ◽  
pp. 297-303 ◽  
Author(s):  
John T. Sandlund
Keyword(s):  
Young Adults ◽  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphoblastic Lymphoma ◽  
Adolescents And Young Adults ◽  
Large B Cell Lymphoma ◽  
Age Related ◽  
Large B Cell

Abstract The SEER (Surveillance, Epidemiology, and End Results) data for the years 1975–1998 show that children with non-Hodgkin lymphoma (NHL) have a better treatment outcome than do adults. Many factors may contribute to this age-related difference. Some factors are related to the patient (e.g., drug distribution and clearance, performance status, compliance, sex) whereas others pertain to tumor histology and biology. The spectrum of NHL subtypes is well known to differ in children and adults. From ages 5 through 14 years, Burkitt lymphoma is the predominant histologic subtype, whereas diffuse large B-cell lymphoma is most common in the 15- to 29-year age range. Because different treatment strategies are often used in children and adults with NHL, the choice of therapy for adolescents and young adults (ages 15 through 29 years) is challenging and somewhat controversial. It is reasonable to consider pediatric strategies for some adolescents and very young adults with NHL, and pediatric strategies are currently used to treat adults with certain subtypes of NHL (Burkitt lymphoma, lymphoblastic lymphoma). However, the use of pediatric strategies in adults does not guarantee a comparable outcome, as illustrated by trials for adult lymphoblastic lymphoma. There is clearly a need for further biologic study of NHL in children, adolescents, and young adults. Age-related differences in tumor biology have been demonstrated in anaplastic large-cell lymphoma (ALCL) and diffuse large B-cell lymphoma (DLBCL). Additional biologic data will not only improve prognosis and treatment stratification but, more important, will lead to the identification of specific molecular targets for therapy.

scholarly journals The Distinction between Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma with c-myc Rearrangement

2002 ◽  
Vol 15 (7) ◽  
pp. 771-776 ◽  
Author(s):  
Naoya Nakamura ◽  
Hirokazu Nakamine ◽  
Jun-ichi Tamaru ◽  
Shigeo Nakamura ◽  
Tadashi Yoshino ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica ◽  
2017 ◽  
Vol 102 (7) ◽  
pp. 1247-1257 ◽  
Author(s):  
Richard A. Noble ◽  
Natalie Bell ◽  
Helen Blair ◽  
Arti Sikka ◽  
Huw Thomas ◽  
...  
Keyword(s):  
B Cell ◽  
Burkitt Lymphoma ◽  
Therapeutic Approach ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document